Information Provided By: 
Fly News Breaks for April 25, 2019
ALXN
Apr 25, 2019 | 15:58 EDT
Piper Jaffray analyst Christopher Raymond says Alexion Pharmaceuticals reported "another strong quarter" and its seventh consecutive quarterly raise. The commercial story is playing out as hoped, and management is taking a characteristically conservative approach to guidance, Raymond tells investors in a research note. He remains a buyer of the stock to levels approaching $180 and keeps an Overweight rating on the name. Alexion remains the analyst's top large-cap pick. The stock in late day trading is up 4% to $135.30.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
